How Could the Federal Limitations on Intoxicating Hemp Reshape Cannabis Investments?

What’s Changing and Why It Matters Now

The new federal funding bill is slated to close that loophole entirely by late 2026. This would phase out most intoxicating hemp products, restrict synthesized cannabinoids, and re-center THC regulation within formal cannabis systems.

Crucially, this shift is happening at the same time rescheduling chatter continues to trend upward, with no new negative federal signals. For investors, the takeaway is twofold:

• The intoxicating-hemp market is shrinking — not THC demand.
• A more regulated path for THC products strengthens the investment case for licensed cannabis operators.

This positions the sector for a potential transition: from a loophole-built market to a more coherent, federally aligned cannabis framework.

Why Did the Feds Clamp Down So Hard on Hemp, and What Does It Mean for Your Cannabis Portfolio?

If you have exposure to U.S. plant-touching companies, you're no stranger to headline whiplash and this late-2025 change adds uncertainty that can add volatility to an already volatile space.

The intoxicating hemp scene had ballooned into a $28 billion unregulated market, undercutting state-licensed players on price and ease of access¹⁰. We're talking a market that rivals the entire regulated cannabis industry in some estimates, pulling in consumers who skip dispensaries for corner-store convenience.

• Cheap hemp alternatives have been squeezing prices on regulated products.
• They've muddied the waters for shoppers, blurring lines between hemp and full-on cannabis.
• Money that could flow to compliant cannabis companies has been siphoned off by non-regulated hemp firms instead.

The new hemp regulations will undoubtedly hit the intoxicating-hemp sector hard, but that doesn’t mean the broader THC market is contracting. If anything, the shift underscores how unsustainable the loophole era had become. Consumers have made it crystal clear that they want THC, the hemp boom proved that, but it shouldn’t come from an unregulated pipeline where potency, safety, and quality vary wildly, and legitimate operators compete with gas-station gummies.

Cleaning up the hemp loophole doesn’t shrink demand; it channels it. A consistent, science-based framework for THC products, paired with cannabis rescheduling to Schedule III or potentially descheduling, is how you replace a fragile, work-around market with a real, federally aligned industry. One that protects consumers, supports compliant operators, and gives the cannabis sector the structure it needs to scale sustainably.

Might the Federal Hemp Ban Level the Field for Licensed Operators…or Stir Up Fresh Head(lines)aches?

The good, the bad, and the unknown:

• Removing intoxicating hemp products from shelves and websites might cut down on easily accessible cannabis substitutes, nudging folks toward licensed channels, where products are regulated and tested for contaminants or impurities.
• A tidier retail scene could steady prices and clear up consumer confusion.
• Holdings in ETFs like those with Trulieve, Green Thumb Industries, Curaleaf, or Cresco Labs might feel less drag from cheap, unregulated “knockoffs.”⁵

• Some consumers who’ve relied on cheap, unregulated intoxicating-hemp products may take time to transition into legal channels, and a portion could drift toward illicit markets if access suddenly tightens.³
• Closing the loophole will create an unmet demand for THC products — especially in states that still lack modern cannabis laws — pushing consumers either toward neighboring regulated markets or toward pressuring their representatives to establish safe, legal options at home.
• It’s still developing: uncertainty remains around how much pushback will come from hemp producers, and whether this ultimately leads to aligned interests between regulated cannabis operators and parts of the hemp industry.

How does Cannabis Rescheduling Factor In?

While the hemp provision drew attention, the more consequential narrative for the industry remains the ongoing potential for federal cannabis rescheduling. Rather than signaling a step backward, some in the sector view the move as part of a broader effort to bring clarity to a marketplace long muddied by the 2018 Farm Bill loophole. By tightening rules around unregulated intoxicating hemp products, policymakers may be clearing the runway for a more coherent, regulated cannabis framework, one where rescheduling fits naturally.

And the backdrop for reform couldn’t be stronger. Public support for cannabis has climbed from single-digit approval in the late 1960s to record highs today. This sustained shift in sentiment continues to anchor the argument that federal policy is due to evolve, especially following HHS’s recommendation to move cannabis to Schedule III.

For U.S.MSOs, rescheduling represents a meaningful catalyst:

• Potential relief from 280E
• Improved profitability
• Expanded access to traditional banking and capital.

Operators in states such as Florida, Ohio, Pennsylvania, and Maryland could benefit substantially from these structural changes.

Globally diversified companies like Tilray and Canopy Growth may also see improved sentiment, though U.S. operators remain the most directly tied to the impact of federal reforms.

Across the sector, investors are increasingly looking beyond regulatory noise and toward the possibility of a more unified, federally aligned cannabis market, one where recent policy steps may ultimately help support a smoother transition.

Balancing Clarity and Chaos in Cannabis Policy

For ETF investors eyeing cannabis exposure, the new hemp restrictions bring a dose of structure (fewer gray-area competitors) alongside fresh uncertainties (federal tone, rollout glitches, consumer pivots).⁸

It doesn't hand-deliver better numbers for regulated companies, but it does usher in a new chapter that could touch:

●       Price stability

●       Demand flows

●       Market buzz

●       How firms deploy capital

Like any policy-heavy arena, stay alerted to operator responses, state moves, and federal follow-through over the next 12–18 months. The cannabis story is still unfolding, full of potential amid the pitfalls, worth watching if it aligns with your risk appetite.

The opinions expressed in this publication are those of the authors and are subject to change. They do not purport to reflect the opinions or views of ETF Central or its members. ETF Central does not guarantee the accuracy, completeness, or reliability of the information provided.

Sources:

¹ Clark Hill. Small, Craig. Hemp Industry Alert: Federal Ban on Hemp-Derived THC Products – Immediate Action Required. November 2025.

² CannaMD. Walters, Jessica. What Does the Hemp THC Ban ACTUALLY Say? November 2025.

³ CNBC. Fountain, Luke. Congressional hemp restrictions threaten $28 billion industry, sending companies scrambling. November 2025.

⁴ JD Supra. BlankRome. Closing the Hemp Loophole: What Monday’s Farm Bill Update Means for Delta-8 and Hemp-Derived THC. November 2025.

⁵ MJBiz. Marijuana operators not waiting for federal hemp ban to halt THCA sales. November 2025.

⁶ ABC News. Wang, Selina. THC gummies and drinks face ban under provision in government spending bill. November 2025.

⁷ Marijuana Moment. Jaeger, Kyle. Congressional Lawmakers Want Exemption From Federal Hemp THC Ban For States With Regulations. November 2025.

⁸ AFS Law. Grosso, David. Top 10 Issues in the Cannabis Industry for 2025. March 2025.

⁹ Hub. Outlook Cannabis. In a volatile marketplace, risk mitigation will separate success from failure. February 2025.

¹⁰ AXIOS. Economy. Lalijee, Jason. Killed "THC loophole" could hurt states, businesses, cannabis advocates say. November 2025.

¹¹ Gallup. Social & Policy Issues. Americans Much More Positive About Progress on Drugs. November 2025.

¹² Morningstar Direct.